Reliv Releases Results of Study on Lunasin
View Reliv International Profile
9/21/2013
Chesterfield, MO September 19, 2013 -- Reliv International, Inc., a maker of nutritional supplements that promote optimal health, today released the results of a promising new study. In the University of Missouri study, pigs supplemented daily with Reliv Now® and LunaRich X™ for eight weeks showed significant improvement in key biomarkers associated with cardiovascular and metabolic health.
Reliv Now is a daily nutritional supplement that delivers an array of protein, vitamins, minerals and antioxidants while optimizing bioactive lunasin content. LunaRich X is the most concentrated form of bioactive lunasin available today. Lunasin is a naturally occurring peptide researchers have identified as the key to soy’s documented health benefits, from cholesterol reduction to general cellular health. In July 2013 Reliv International acquired exclusive rights to the lunasin used in these products.
“While this was a small animal study and only a preliminary step in demonstrating the efficacy of this supplement regimen, the dramatic results are remarkable,” said Dr. Alfredo Galvez, lead scientific advisor of SL Technology Inc, a Reliv subsidiary. “Most exciting of all is that there currently exist no effective treatments for improving key biomarkers measured in the study, namely circulating free fatty acids and the hormones leptin and adiponectin.”